KMKoji Mitsuzuka

Koji Mitsuzuka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Koji Mitsuzuka has a total of 146 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non‐muscle‐invasive bladder cancer: A retrospective multicenter study

    by Takuma Sato, Takeshi Sano, Sadafumi Kawamura, Yoshihiro Ikeda, Kazuhiko Orikasa, Takaki Tanaka, Atsushi Kyan, Shozo Ota, Satoru Tokuyama, Hideo Saito, et al.

    Objectives: Clinical guidelines recommend that patients with non‐muscle‐invasive bladder cancer (NMIBC) should be treated with appropriate adjuvant therapy. However, compliance with guideline recommendations is insufficient, and this may lead to unfavorable outcomes. We aimed to investigate the level of adherence to guideline recommendations in patients with NMIBC and evaluate the outcomes of those who did and did not receive guideline‐recommended therapies.Methods: We performed a retrospective analysis of patients with histologically diagnosed NMIBC. The percentage of patients with intermediate‐ and high‐risk tumors who received adjuvant intravesical therapy or second transurethral resection (TUR) was calculated. Recurrence‐free survival was assessed in patients who did and did not receive the therapies. We conducted a propensity score‐matched analysis to compare outcomes between patients with intermediate‐risk and T1 NMIBC who did and did not undergo guideline‐recommended therapies.Results: Overall, 1204 patients from the Tohoku Urological Evidence‐Based Medicine Study Group and Kyoto University Hospital were included. Of patients with intermediate‐ and high‐risk tumors, 91.0% and 74.0% did not receive maintenance bacillus Calmette–Guérin (BCG), respectively. In both groups, significantly better recurrence‐free survival was found for patients treated with maintenance BCG. Among patients with T1 NMIBC, only 16.7% underwent guideline‐recommended therapies, that is, a second TUR and maintenance BCG. Significantly greater recurrence‐free survival was observed in patients who received guideline‐recommended therapies compared with propensity‐matched patients who did not.Conclusions: Guideline‐recommended therapies may contribute to improvements in outcomes for patients with NMIBC, suggesting that improvements in adherence to clinical guidelines may lead to favorable outcomes.


  • Trends in the use of local intervention for metastatic hormone‐naïve prostate cancer: A multicenter retrospective study

    by Ryuma Tanaka, Shingo Hatakeyama, Shintaro Narita, Toshihiko Sakurai, Toshikazu Tanaka, Hikari Miura, Takuya Oishi, Sadafumi Kawamura, Senji Hoshi, Shigeto Ishidoya, et al.

    Objective: To evaluated the trends of local intervention and their impact on oncological outcomes in metastatic hormone‐naïve prostate cancer (mHNPC) in real‐world practice.Methods: This retrospective multicenter study included 760 patients treated with either androgen deprivation therapy (ADT) without local treatment (no castration‐resistant prostate cancer [CRPC] progression within 12 months, control group) or ADT plus local intervention (intervention group) between January 2005 and March 2022. We evaluated the trends in the use of local intervention in patients with mHNPC and factors associated with CRPC‐free survival in the intervention group.Results: The use of local intervention gradually increased in combination with upfront combination treatment (docetaxel or androgen receptor axis‐targeted agents) for the duration of our study. The number of patients with local intervention combined with upfront treatment was significantly higher in patients with high tumor burden disease than in those with low tumor burden disease. Of the 108 patients who received local intervention, a duration of ≤7 months of initial therapy before local intervention and a level of prostate‐specific antigen ≥0.20 ng/mL at the time of local intervention were significantly associated with poor CRPC‐free survival.Conclusions: The use of local intervention in combination with upfront therapy to treat mHNPC increased for the duration of our study regardless of the tumor burden. Local intervention in addition to the standard of care for mHNPC may be a feasible treatment option for selected patients, taking into consideration the duration of and response to initial treatment.


  • Minimal residual membranous urethral length and membranous urethral length predict poor recovery from incontinence after robot‐assisted radical prostatectomy and after open radical prostatectomy

    by Eiichiro Ohara, Naoki Kawamorita, Yohei Satake, Yasuhiro Kaiho, Koji Mitsuzuka, Hideo Saito, Shigeto Ishidoya, Yoichi Arai, Akihiro Ito

    Objectives: To investigate how much minimal residual membranous urethral length (mRUL) and maximal urethral length (MUL) measured on MRI preoperatively affect postoperative urinary incontinence (PUI) and recovery in robot‐assisted radical prostatectomy (RARP) and open radical prostatectomy (ORP).Methods: The subjects were 190 and 110 patients undergoing RARP and ORP, respectively, in our institution. Patients underwent preoperative MRI for prostate cancer evaluation and completed the quality of life questionnaire of the Expanded Prostate Cancer Index Composite instrument before and 1, 3, 6, and 12 months after surgery. The parameters of mRUL and MUL were measured on MRI and analyzed along with other parameters including age, body mass index, and nerve sparing.Results: The median mRUL and MUL were 7.81 and 14.27 mm in the RARP group and 7.15 and 13.57 mm in the ORP group, respectively. Recovery rates from PUI were similar in the two groups. Multivariate analyses showed that mRUL was a predictor of baseline continence, whereas shorter MUL was a predictor of poor recovery from PUI. Patients with both shorter mRUL and MUL had significantly worse recoveries from PUI after RARP and ORP than patients with longer mRUL and MUL.Conclusions: Minimal residual membranous urethral length contributes to urethral function as basal urinary continence, whereas MUL represents the potential of recovery from PUI in RARP and ORP. The MUL measured by preoperative MRI can predict poor recovery from PUI after radical prostatectomy and combined evaluation of MUL and mRUL support to anticipate poor recovery of PUI.


  • Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS‐JAPAN study

    by Takuma Kato, Akira Yokomizo, Ryuji Matsumoto, Yoichiro Tohi, Jimpei Miyakawa, Koji Mitsuzuka, Hiroshi Sasaki, Junichi Inokuchi, Masafumi Matsumura, Shinichi Sakamoto, et al.

    Objectives: To compare the medical costs of active surveillance with those of robot‐assisted laparoscopic prostatectomy, brachytherapy, intensity‐modulated radiation therapy, and hormone therapy for low‐risk prostate cancer.Methods: The costs of protocol biopsies performed in the first year of surveillance (between January 2010 and June 2020) and those of brachytherapy and radiation therapy performed between May 2019 and June 2020 at the Kagawa University Hospital were analyzed. Hormone therapy costs were assumed to be the costs of luteinizing hormone‐releasing hormone analogs for over 5 years. Active surveillance‐eligible patients were defined based on the following: age <74 years, ≤T2, Gleason score ≤6, prostate‐specific antigen level ≤10 ng/ml, and 1–2 positive cores. We estimated the total number of active surveillance‐eligible patients in Japan based on the Japan Study Group of Prostate Cancer (J‐CAP) study and the 2017 cancer statistical data. We then calculated the 5‐year treatment costs of active surveillance‐eligible patients using the J‐CAP and PRIAS‐JAPAN study data.Results: In 2017, number of active surveillance‐eligible patients in Japan was estimated to be 2808. The 5‐year total costs of surveillance, prostatectomy, brachytherapy, radiation therapy, and hormone therapy were 1.65, 14.0, 4.61, 4.04, and 5.87 million United States dollar (USD), respectively. If 50% and 100% of the patients in each treatment group had opted for active surveillance as the initial treatment, the total treatment cost would have been reduced by USD 6.89 million (JPY 889 million) and USD 13.8 million (JPY 1.78 billion), respectively.Conclusion: Expanding active surveillance to eligible patients with prostate cancer helps save medical costs.


  • Open Access

    Correction to: The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study

    by Yoichiro Tohi, Takuma Kato, Ryuji Matsumoto, Nobuo Shinohara, Kenichiro Shiga, Akira Yokomizo, Masaki Nakamura, Haruki Kume, Koji Mitsuzuka, Hiroshi Sasaki, et al.

  • Pathological and oncological outcomes of off-criteria radical prostatectomy in patients opting for active surveillance: From PRIAS-JAPAN.

    by Yoichiro Tohi, Takuma Kato, Masaki Nakamura, Ryuji Matsumoto, Hiroshi Sasaki, Koji Mitsuzuka, Junichi Inokuchi, Katsuyoshi Hashine, Akira Yokomizo, Hidefumi Kinoshita, et al.

    250 Background: Trigger for definitive treatment in active surveillance (AS) is strictly criteria-based, but some patients might be surgically treated without adherence to the criteria. We aimed to evaluate whether oncological outcomes differ depending on adherence to the criteria in patients who opting for AS. Methods: We retrospectively reviewed data of 1,035 patients enrolled in a prospective cohort of PRIAS-JAPAN. Of 162 patients underwent radical prostatectomy, 136 patients were analyzed, excluding those with Gleason score 3+4 at diagnosis, RP within one year of enrollment. Triggers for RP due to pathological reclassification on repeat biopsy was defined as on-criteria. We compared pathological findings on RP and prostate specific antigen (PSA) recurrence-free survival of on-criteria with off-criteria. Results: Off-criteria was 35 patients (24.7%). There were significant differences in the median time to RP (16 vs. 18.5 months, p0.999) were not significantly different. At a median postoperative follow-up of 36 months, no significant difference in PSA recurrence-free survival was found (log-rank p = 0.828). Conclusions: Although half of off-criteria patients underwent RP within 3 years of starting AS, their oncological outcomes were not different from on-criteria. Our result suggested the potential for tailoring the inclusion criteria of AS within the strict protocol. Clinical trial information: 000002874.

  • Comparison of the medical costs between active surveillance and other treatment for early prostate cancer in Japan: From the data of PRIAS JAPAN study.

    by Takuma Kato, Mikio Sugimoto, Yoshiyuki Kakehi, Yoichiro Tohi, Ryuji Matsumoto, Nobuo Shinohara, Akira Yokomizo, Hiroshi Fukuhara, Koji Mitsuzuka, Hiroshi Sasaki, et al.

    280 Background: As the number of prostate cancer patients increases, the cost of treatment is becoming an urgent issue. To compare the costs between active surveillance, robot-assisted laparoscopic prostatectomy (RALP), Brachytherapy (BT), Intensity Modulated Radiation Therapy (IMRT), and Androgen deprivation therapy(ADT). Methods: The costs of protocol biopsies in the first year of AS performed between January 2010 and June 2020, and the treatment costs of RALP, BT, and IMRT performed between May 2019 and June 2020 at Kagawa university hospital were analyzed. The cost of ADT was assumed to be the cost of the LH-RH analog over 5 years. The inpatient treatment cost for each treatment was calculated from our DPC data, and for IMRT, the treatment cost was calculated by the outpatient cost at the time of irradiation. AS-eligible patients were defined as less than 74 years old, less than T2, less than GS6, and less than two positive cores. We estimated the total number of AS-eligible patients in Japan based on the data of the J-CAP study and the data of cancer statistics in 2017 and estimated the total treatment cost of AS-eligible patients based on the data of treatment breakdown of T1/T2 patients in the J-CAP study. In addition, we used the data from PRIAS-JAPAN to calculate the AS continuation rate, protocol biopsy acceptance rate, and the breakdown of secondary treatments. We simulated the 5-year treatment cost for AS patients using the system. Results: The median treatment costs for AS (n = 45), RALP (n = 68), BT (n = 27), and IMRT (n = 44), and ADT were US$1.24 thousand, US$ 14.6 thousand, US$14.8 thousand, US$ 12.9 thousand, and US$8.16, respectively. The number of AS-eligible patients in Japan was estimated to be 5414, and the total cost of AS, RALP, BT, IMRT, HT, and ADT over 5 years was estimated to be US$3.07 million, US$34.8 million, US$8.46 million, US$11.09 million, and US$14.05 million, respectively. If 50% and 100% of the patients in each treatment group chose AS as their first treatment, the total cost of treatment would be reduced by US$18.6 million and US$38.5 million, respectively. Conclusions: The prevalence of AS will contribute to reducing the cost of prostate cancer treatment.

  • Efficacy of combined androgen blockade therapy in patients with metastatic hormone‐sensitive prostate cancer stratified by tumor burden

    by Yoshiyuki Nagumo, Mizuki Onozawa, Takahiro Kojima, Naoki Terada, Masaki Shiota, Koji Mitsuzuka, Hiroaki Yasumoto, Hiroaki Matsumoto, Hideki Enokida, Takayuki Sugiyama, et al.

    Objective: To determine the effect of combined androgen blockade with a first‐generation anti‐androgen on the prognoses of metastatic hormone‐sensitive prostate cancer patients stratified by tumor burden.Methods: We retrospectively analyzed the cases of metastatic hormone‐sensitive prostate cancer patients who were treated with androgen deprivation therapy in 2008–2017 at 30 institutions in Japan. To compare the overall survival and progression‐free survival rates of the patients treated with castration monotherapy and combined androgen blockade, we carried out a Cox proportional hazards regression analysis using both inverse probability of treatment weighting and instrumental variables methods. High‐burden disease was defined as the presence of four or more bone metastases and/or visceral metastasis.Results: Of 2048 patients, 702 (34.3%) and 1346 (65.7%) patients were classified as the low‐ and high‐burden groups, respectively. In each group, >80% of the patients were treated with combined androgen blockade. Although there was no significant between‐group difference in the overall survival according to the androgen deprivation therapy method, in the high‐burden group the progression‐free survival of the combined androgen blockade‐treated patients was significantly better than that of patients treated with castration monotherapy: inverse probability of treatment weighting method, hazard ratio 0.49, 95% confidence interval 0.34–0.71; instrumental variables method, hazard ratio 0.80, 95% confidence interval 0.60–0.98.Conclusion: In the high‐burden group, combined androgen blockade with a first‐generation anti‐androgen resulted in superior progression‐free survival compared with castration monotherapy. For well‐selected metastatic hormone‐sensitive prostate cancer patients, the use of combined androgen blockade might still have some suitable scenarios.


  • Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone‐sensitive prostate cancer with Gleason score ≥8

    by Kento Morozumi, Koji Mitsuzuka, Shintaro Narita, Masahiro Takahashi, Sadafumi Kawamura, Tatsuo Tochigi, Yoichi Arai, Senji Hoshi, Jiro Shimoda, Shigeto Ishidoya, et al.

    Objective We evaluated the impact of Gleason pattern 5 presence on prognosis among de novo metastatic hormone-sensitive prostate cancer patients with a Gleason score ≥8. Methods The data of 559 patients diagnosed as metastatic hormone-sensitive prostate cancer with a Gleason score ≥8, who were initially treated with androgen deprivation therapy from 2008 to 2016, were retrospectively collected. Patients were divided into two groups as high and low volume based on the CHAARTED trial criteria. Results The median overall survival of the 559 metastatic hormone-sensitive prostate cancer patients with Gleason score ≥8 was 70 months, with a median follow-up period of 36 months. Gleason pattern 5 was confirmed in 341 patients (61.0%), in which primary Gleason pattern 5 was confirmed in 164 patients (29.3%). The number of patients with high metastatic volume group was 363 (64.9%). In total and high metastatic volume groups, hemoglobin and lactate dehydrogenase were significant factors for predicting overall survival, but both Gleason pattern 5 and primary Gleason pattern 5 did not show a statistically significant difference. In the low-volume metastatic group, the median overall survival in patients with or without primary Gleason pattern 5 was 40 and 78 months, respectively. In multivariate analysis, only primary Gleason pattern 5 was an independent predictive factor for overall survival in the low-volume metastatic group (hazard ratio 2.76, 95% confidence interval 1.88–8.67; P = 0.0026). Conclusion The presence of Gleason pattern 5 was not associated with overall survival in metastatic hormone-sensitive prostate cancer with a Gleason score ≥8. In low-metastatic volume metastatic hormone-sensitive prostate cancer, primary Gleason pattern 5 was a poor prognostic factor, which might show a separate treatment option for this group.


  • Open Access

    Characteristics of α2,3‐sialyl N‐glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level

    by Tohru Yoneyama, Hayato Yamamoto, Mihoko Sutoh Yoneyama, Yuki Tobisawa, Shingo Hatakeyama, Takuma Narita, Hirotake Kodama, Masaki Momota, Hiroyuki Ito, Shintaro Narita, et al.

    Background: The presence of glycosylated isoforms of prostate‐specific antigen (PSA) in prostate cancer (PC) cells is a potential marker of their aggressiveness. We characterized the origin of α2,3‐sialylated prostate‐specific antigen (S23PSA) by tissue‐based sialylation‐related gene expression and studied the performance of S23PSA density (S23PSAD) alone and in combination with multiparametric magnetic resonance imaging (MRI) for the detection of clinically significant prostate cancer in men with elevated PSA.Methods: Tissue‐based quantification of S23PSA and sialyltransferase and sialidase gene expression was evaluated in 71 radical prostatectomy specimens. The diagnostic performance of S23PSAD was studied in 1099 men retrospectively enrolled in a multicenter systematic biopsy (SBx) cohort. We correlated the S23PSAD with Prostate Imaging Reporting and Data System (PI‐RADS) scores in 98 men prospectively enrolled in a single‐center MRI‐targeted biopsy (MRI–TBx) cohort. The primary outcome was the PC‐diagnostic performance of the S23PSAD, the secondary outcome was the avoidable biopsy rate of S23PSAD combined with DRE and total PSA (tPSA), and with or without PI‐RADS.Results: S23PSA was significantly higher in Gleason pattern 4 and 5 compared with benign prostate tissue. In the retrospective cohort, the performance of S23PSAD for detecting PC was superior to tPSA or PSA density (PSAD) (AUC: 0.7758 vs. 0.6360 and 0.7509, respectively). In the prospective cohort, S23PSAD was superior to tPSA, PSAD, and PI‐RADS (AUC: 0.7725 vs. 0.5901, 0.7439 and 0.7305, respectively), and S23PSAD + PI‐RADS + DRE + tPSA was superior to DRE + tPSA+PI‐RADS with avoidance rate of MRI–TBx (13% vs. 1%) at 30% risk threshold.Conclusions: The diagnostic performance of S23PSAD was superior to conventional strategies but comparable to mpMRI.